Clinical Trial: H002-101

Trial Status: Open
Disease Type: Lung
Trial ID H002-101
Sponsor ID Hongyun Biotech

A Phase 1/2a, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Preliminary Anti-Tumor Activity of H002 in Patients with Active Epidermal Growth Factor Receptor Mutation Locally Advanced or Metastatic Non-Small Lung Cancer

1 Location

Locations

Fairfax Office

Learn More About This Trial

Other Relevant Trials
Trial ID 61186372NSC3004
Sponsor ID Paloma 3

A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy

1 Location
Trial ID 21318
Sponsor ID Roche Laboratories, Inc.

A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Principal Investigator
Timothy A. McCarthy, MD
5 Locations